FDA to Review Spectrum Pharma Beleodaq Zacks.com The candidate is being developed as a conditioning agent for stem cell transplant and multiple myeloma. The company expects to report top-line data from a pivotal study on captisol-enabled melphalan in the second quarter of 2014. Spectrum Pharma ... |
